These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 33025952

  • 1. Levonadifloxacin arginine salt to treat acute bacterial skin and skin structure infection due to S. aureus including MRSA.
    Saxena D, Kaul G, Dasgupta A, Chopra S.
    Drugs Today (Barc); 2020 Sep; 56(9):583-598. PubMed ID: 33025952
    [Abstract] [Full Text] [Related]

  • 2. In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms.
    Tellis M, Joseph J, Khande H, Bhagwat S, Patel M.
    J Med Microbiol; 2019 Aug; 68(8):1129-1136. PubMed ID: 31241446
    [Abstract] [Full Text] [Related]

  • 3. Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence.
    Bhagwat SS, Nandanwar M, Kansagara A, Patel A, Takalkar S, Chavan R, Periasamy H, Yeole R, Deshpande PK, Bhavsar S, Bhatia A, Ahdal J, Jain R, Patel M.
    Drug Des Devel Ther; 2019 Aug; 13():4351-4365. PubMed ID: 31920285
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study.
    Bhatia A, Mastim M, Shah M, Gutte R, Joshi P, Kumbhar D, Periasamy H, Palwe SR, Chavan R, Bhagwat S, Patel M, Llorens L, Friedland HD.
    J Assoc Physicians India; 2020 Aug; 68(8):30-36. PubMed ID: 32738837
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Assessment of antibacterial activity of levonadifloxacin against contemporary gram-positive clinical isolates collected from various Indian hospitals using disk-diffusion assay.
    Baliga S, Mamtora DK, Gupta V, Shanmugam P, Biswas S, Mukherjee DN, Shenoy S.
    Indian J Med Microbiol; 2020 Aug; 38(3 & 4):307-312. PubMed ID: 33154240
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
    Patel MV, De Souza NJ, Gupte SV, Jafri MA, Bhagwat SS, Chugh Y, Khorakiwala HF, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4754-61. PubMed ID: 15561853
    [Abstract] [Full Text] [Related]

  • 17. In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections.
    McCurdy S, Lawrence L, Quintas M, Woosley L, Flamm R, Tseng C, Cammarata S.
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630189
    [Abstract] [Full Text] [Related]

  • 18. In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital.
    Mamtora D, Saseedharan S, Rampal R, Joshi P, Bhalekar P, Ahdal J, Jain R.
    J Lab Physicians; 2020 Dec; 12(3):230-232. PubMed ID: 33268943
    [Abstract] [Full Text] [Related]

  • 19. Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin.
    Mehta Y, Mishra KC, Paliwal Y, Rangappa P, Sinha S, Bhapkar S.
    Crit Care Res Pract; 2022 Dec; 2022():2668199. PubMed ID: 36785544
    [Abstract] [Full Text] [Related]

  • 20. Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection.
    Bhawsar S, Kale R, Deshpande P, Yeole R, Bhagwat S, Patel M.
    Bioorg Med Chem Lett; 2021 Dec 15; 54():128432. PubMed ID: 34757217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.